ProImmune REVEAL® MHC-Peptide

Competition Binding Assays

How Strong is Your Competitor?

There are situations when you need to evaluate MHC-binding of peptides not just on its own but how a peptide or peptide-mimetic competes with a known control peptide for binding.

As an extension to our regular ProImmune REVEAL® MHC-peptide binding and rate assays we are now also offering MHC-peptide competition binding assays.

These new assays are currently available for the following HLA-DR supertypes:

HLA-DRB1*01:01, *03:01, *04:01, *04:05, *07:01, *09:01, *11:01, *15:01.

Like our other specialist assays our competition assays turn around rapidly in only a few weeks.

ProImmune REVEAL® Competition Assay Principle

Figure 1. Competition assay principle: A labelled control peptide is bound to the MHC-complex, giving a high baseline signal in an immunoassay. As the peptide is competed away with unlabelled competitor peptide the signal reduces at increasing concentration of competitor peptide. The control peptide is usually a well known HLA-Class II restricted immunodominant T cell epitope which is further known to be restricted to the HLA-DR supertype of interest.

Figure 2. Example data for the assay. Half-life is determined using 12 competitor concentrations and single time constant off rate curve.

Additional Features:

The assay can be adapted to accommodate a range of requirements:

 Control peptides can be chosen depending on the assay objective

 Test peptide or compounds provided by customer or made by ProImmune

 The concentration range can be varied to suit the specific project objective

 Mixtures of peptides as well as mono-disperse peptides can be tested

Key Publication for the Competition Assay:

Jansson L., Wraith D., et al. (2018). “Immunotherapy With Apitopes Blocks the Immune Response to TSH Receptor in HLA-DR Transgenic Mice”   Endocrinology, Volume 159, Issue 9, Sep., pp 3446–3457

See ProImmune REVEAL® and ProVE customer publications